Texas Oncology’s Dr. Debra Patt weighed in with Fierce Healthcare on where the oncology ecosystem stands on the Trump administration’s most-favored-nation final rule Read the full article here.Read more
ADVI Health estimates year one of the Most Favored Nations (MFN) Model could cut Part B drug payments by $4.2 Billion.Read more
Lindsay Bealor Greenleaf discusses the health care policy outlook under a likely split Congress and Biden Administration with Morning ConsultRead more
“This focus on how things are paid for abroad is a general theme across both administrations,” ADVI VP Lindsay Bealor Greenleaf explained to
Fierce Healthcare about drug policy expectations following the Presidential election.